Research Foundation For Mental Hygiene, Inc.

Research Foundation For Mental Hygiene, Inc. operating through its Nathan S Kline Institute Division generates federal grant funding for translational and basic neuroscience research as a prime recipient and sub-recipient, primarily from the National Institutes of Health, with a research footprint concentrated in psychiatric and neurological disorders, aging, and brain imaging methodologies.

The organization is a tax-exempt nonprofit operating division of the parent Research Foundation For Mental Hygiene Inc., headquartered in Orangeburg, New York, with a secondary administrative location in Menands, New York. The Nathan S Kline Institute Division does not hold federal contracts; its federal footprint is entirely grant-funded research. The organization competes in open grant competitions across multiple NIH institutes and does not operate under set-aside categories.

The research portfolio spans concrete capability domains grounded in recent award history. The National Institute of Mental Health funds schizophrenia research including sensory contributions to third visual pathway dysfunction ($778,548 through July 2030), virtual reality mindfulness applications for aggression in schizophrenia ($745,840 through May 2027), auditory event-related potentials for circuit engagement in therapeutic development (two awards from 2023–2025), circuit-specific chemogenetic neuromodulation in nonhuman primates as a cooperative agreement, and a schizophrenia extension study for the NKI Rockland Sample II generating open multimodal brain imaging and physiology datasets. The National Institute on Aging funds Alzheimer's disease research including high-frequency oscillations as biomarkers ($454,024 through August 2026), apolipoprotein E genotype modulation of brain mitovesicle production ($2.499 million through August 2027), hyperexcitability mechanisms, extracellular vesicle biology, and circuit mechanisms of brain rhythms in aging. The National Institute on Neurological Disorders and Stroke funds temporal lobe epilepsy research on mossy cell circuits and focused ultrasound delivery of designer receptors to primate CNS. The Institute also received $3.74 million from the National Science Foundation for development of a next-generation 9.4 Tesla magnetic resonance imaging system completed in 2026, and cooperative agreement funding from the Research Development and Engineering Command for integrated hippocampal and motor cortex circuit studies.

Customer concentration is highly concentrated within NIH. The National Institute of Mental Health accounts for 55 awards (31% of the prime and sub portfolio), followed by NIMH parent agency funding (35 awards), the National Institute on Aging (24 awards), the National Institute of Child Health and Human Development (9 awards), and the National Institute on Drug Abuse (9 awards). Together these five customer entities account for 76% of all awards in the source data. The combined potential value across all 174 awards is reported in the source as $15 thousand, an apparent data error; dollars obligated across all awards total $298.8 million, indicating substantial realized funding. The source lists only $15 thousand in "potential value," suggesting the portfolio consists predominantly of completed or currently executing grants rather than remaining ceiling on open vehicles.

Activity has grown sharply from 4 awards in 2022 to 34 in 2024, with 20 awards in 2025 and 11 recorded through mid-2026. Sixteen awards face ultimate completion within the next twenty-four months, representing recompete opportunity. The prime-to-sub split runs 56% prime (98 awards) and 44% sub (76 awards), with the sub awards concentrated under New York University as prime grantee, indicating deep integration into NYU-led research networks. Notable sub-award partners include Columbia University, UC Davis, University of Tennessee, Icahn School of Medicine at Mount Sinai, Friends Research Institute, and Old Dominion University, across neuroscience, computational modeling, drug development, and public health research domains.

The research infrastructure capability portfolio centers on advanced neuroimaging (9.4 Tesla MRI, functional MRI, fMRI-guided stimulation), neuromodulation platforms (transcranial focused ultrasound, transcranial magnetic stimulation, transcranial electrical stimulation, designer receptors/DREADDs, chemogenetics), electrophysiology (EEG, high-density electrode arrays, single-unit recording), and animal model behavioral phenotyping. The Institute maintains an Animal Care Program working toward AAALAC accreditation and operates digital ventilated caging systems for longitudinal mouse monitoring. Methodological expertise spans in vivo preclinical assays, computational neuroscience for circuit modeling, and multimodal neuroimaging integration in human and nonhuman primate studies.

Human subjects research spans lifespan cohorts—the NKI Rockland Sample II collects data from ages 6 to 85 years—and patient populations with schizophrenia, treatment-resistant depression, major depressive disorder, and substance use disorders. The Institute has generated open-access datasets and is positioned as a regional neuroscience facility supporting Columbia, NYU, and Cornell research communities in the New York City tri-state area.